Search results

1862 results

Sorted by Relevance . Sort by Date

  1. Scleroderma: oral mycophenolate (ESUOM32)

    Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

  2. Gouty arthritis: canakinumab (ESNM23)

    Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

  3. Type 2 diabetes: lixisenatide (ESNM26)

    Summary of the evidence on lixisenatide (glucagon-like peptide-1 [GLP-1] mimetic) for treating type 2 diabetes to inform local NHS planning and decision-making

  4. Pulmonary sarcoidosis: infliximab (ES2)

    Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

  5. Type 2 diabetes: alogliptin (ESNM20)

    Summary of the evidence on alogliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor) for type 2 diabetes to inform local NHS planning and decision-making

  6. Hypersexuality: fluoxetine (ESUOM46)

    Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making